Psyence Biomedical Invests in Psyence Labs for Ibogaine
The $2.6 million deal supports the development of pharmaceutical-grade ibogaine for clinical use in the United States.
Live Poll
Do you support increased investment in the development of pharmaceutical-grade ibogaine for mental health treatment?